Abstract
Systemic lupus erythematosus is systemic autoimmune disease causing significant morbidity and mortality worldwide, particularly in the women of child-bearing age. It is typically associated with antinuclear antibodies, in particular antidouble-stranded DNA antibodies, which form immune complexes and can cause multiorgan damage by activating various cell types in genetically susceptible individuals. Due to the chronic and heterogenous nature of the condition, clinical trials of novel therapeutics or treatment strategies are challenging, with some newer drugs failing to meet their primary endpoint in trial. SLE manifestations are protean, with the treatment of lupus nephritis (LN) being a priority area for study given its association with end-stage renal failure (ESRF). SLE remains a disease with significant unmet need, but there is hope that the study of larger, well-characterized cohorts along with further genetic and experimental medicine studies, will lead to new treatments and improved patient outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
